• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Topics » Science » Vaccines

Vaccines
Vaccines RSS Feed RSS

COVID-19 vaccine vials

India’s speedy approval of domestic COVID-19 vaccine raises concerns

Jan. 5, 2021
By David Ho
HONG KONG – India’s conditional approval on Jan. 3 of a COVID-19 vaccine developed domestically by Bharat Biotech International Ltd. but still in phase III trials has sparked concerns about its safety. The Drugs Controller General of India (DCGI) gave emergency authorization to the product, Covaxin, along with the Astrazeneca plc and Oxford University vaccine Covishield. The DCGI said the conditional approval granting “restricted use in emergency situation” for Covaxin was done in “clinical trial mode” to account for the fact that the shot is still being tested. But the rush to approve it has created controversy and confusion.
Read More
Gloved hand holding COVID-19 vaccine vial, syringe

Moderna to file for EUA of mRNA-1273 for COVID-19 following primary efficacy analysis

Nov. 30, 2020
Moderna has announced that the primary efficacy analysis of the phase III COVE study of mRNA-1273 conducted on 196 cases has confirmed the high efficacy observed at the first interim analysis (ClinicalTrials.gov Identifier NCT04470427).
Read More
Coronavirus and stock charts

Moderna’s $483M BARDA backing for COVID-19 vaccine bolsters the company stock

April 17, 2020
By Lee Landenberger
The U.S. Biomedical Advanced Research and Development Authority (BARDA) commitment of up to $483 million to accelerate Moderna Inc.’s mRNA vaccine candidate, mRNA-1273, in efforts to fight coronavirus (SARS-CoV-2) would enable the company to supply millions of doses per month in 2020 and tens of millions per month in 2021 if the vaccine candidate is successful in the clinic.
Read More
HIV antiretroviral drugs
CROI 2020

With Uhambo’s and research lessons, once more unto the breach

March 11, 2020
By Anette Breindl
CYBERSPACE – Continuing improvements in HIV treatment and progress toward a cure notwithstanding, an effective vaccine will be necessary to gain the upper hand in the decades-long fight against the pandemic.
Read More

Lasker Foundation honors Herceptin, vaccines, immunology

Sep. 11, 2019
By Anette Breindl
The 2019 Lasker Award winners were announced Tuesday, adding five researchers and GAVI, the Vaccine Alliance, to its roster of Laureates.
Read More

Vaccine trials seek to maximize potential, manage expectations

July 24, 2019
By Anette Breindl
MEXICO CITY – Ten years after the RV144 "Thai trial" was the first to show that an effective HIV vaccine was possible, three efficacy trials for HIV vaccines are once again underway.
Read More

With positive early results, team moves forward on Alzheimer's vaccine

July 1, 2019
By Sergio Held
A research team at the University of New Mexico (UNM), Albuquerque, is moving forward with the development of a vaccine against tauopathies, a neurodegenerative class of diseases that includes Alzheimer's disease, but while promising in the lab, it could take a decade to get an actual vaccine to market.
Read More

A shot in the dark? ‘Flu’ Manchu-type fears of evil pharma, plus frets over strains and safety, keep too many away from vaccine

Oct. 7, 2014
By Randy Osborne
By now I’ve learned to keep my flu shot habit a secret. Every year about this time, since I was 18 years old, I get vaccinated. But long ago I stopped telling people about it, so I don’t have to hear: “Oh, you know the flu vaccines are made of antifreeze [mercury, aluminum, formaldehyde], right?” or “That’s a crazy thing to do, because the shot itself can make you sick!” or – this one’s fairly new – “You don’t really need it if you’ve got a healthy immune system. Anyway flu shots cause Alzheimer’s [in the old] and autism [in...
Read More

What’s 10 minus Four? Not Six, Apparently

Nov. 30, 2012
By Anette Breindl
Dec. 1 is World AIDS Day, and when I reflect on AIDS, I generally do it with a sense of amazement about how far we have come in the treatment of HIV since AIDS first came to the attention of the U.S. medical establishment, in form of a cluster of pneumocystis pneumonia infections in young men, in 1981. An AIDS-free generation is no longer a pipe dream. With all the progress that’s being made, though, I’ve been struck how one thing that seems to keep receding into the distance – like a manifestation of the joke that the future is...
Read More

‘Final Chapter’ on XMRV? Good Luck With That One

Sep. 24, 2012
By Anette Breindl
Viruses are on the border between living and dead. So are the theories about what some of them cause. Two studies were published last week that showed no link between xenotropic murine leukemia virus-related virus (XMRV) and either chronic fatigue syndrome or prostate cancer. The scientific journals consider the matter settled with these studies. In theirs new sections, Nature and PLoS ONE wrote about “the nail in XMRV’s coffin” and “The Final Chapter on XMRV and Prostate Cancer.” Umm . . . good luck with that. Actually, the link between XMRV and prostate cancer may be laid to rest fairly...
Read More
Previous 1 2 3 4 5 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 9, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe